BP
CRNX icon

Ballentine Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ballentine Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Buy
+12,264
New +$456K 0.01% 598

Other funds holding CRNX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Ballentine Partners's CRNX Position: Q2 2026 in Review

Ballentine Partners opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 12,264 shares worth $459K. The stake represents 0.01% of the portfolio and ranks #598 among its holdings.

21 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Ballentine Partners held 12,264 shares of Crinetics Pharmaceuticals worth $459K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Ballentine Partners position in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #598 holding.
  • 21 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.